A Concise Review on Tyrosine Kinase Targeted Cancer Therapy

被引:0
|
作者
Shah, Ashish [1 ]
Patel, Chhagan [2 ]
Parmar, Ghanshaym [1 ]
Patel, Ashish [3 ]
Jain, Manav [4 ]
机构
[1] Sumandeep Vidyapeeth, Dept Pharm, Vadodara, Gujarat, India
[2] Shree Sarvajaink Pharm Coll, Mehsana, Gujarat, India
[3] CHARUSAT, Ramanbhai Patel Coll Pharm, Anand, Gujarat, India
[4] Postgrad Inst Med Educ & Res, Dept Pharmacol, Chandigarh, Punjab, India
关键词
Tyrosine kinase; types of receptors; tyrosine kinase inhibitors; cancer; small molecules; targeted therapy; CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; METASTATIC COLORECTAL-CANCER; SRC FAMILY KINASES; OPEN-LABEL; BREAST-CANCER; DOUBLE-BLIND; 1ST-LINE TREATMENT; MOLECULAR TARGETS; THYROID-CANCER;
D O I
10.2174/1574885517666220331104025
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tyrosine Kinase (TK) is considered one of the important family members of the kinase family due to its important role in various cellular processes like cell growth, cell differentiation, apoptosis, etc. Mutation, overexpression, and dysfunction of tyrosine kinase receptors lead to the development of malignancy; thus, they are considered one of the important targets for the development of anti-cancer molecules. The tyrosine kinase family is majorly divided into two classes; receptor and non-receptor tyrosine kinase. Both of the classes have an important role in the development of tumour cells. Currently, more than 40 FDA-approved tyrosine kinase inhibitors are used to treat various types of cancers. Tyrosine kinase inhibitors mainly block the phosphorylation of tyrosine residue of the corresponding kinase substrate, so activation of downstream signalling pathways can be inhibited. The promising results of tyrosine kinase inhibitors in solid tumours have revolutionized oncology research. In this article, we summarized the role of some important members of the tyrosine kinase family in the development and progression of tumour cells and the significance of tyrosine kinase inhibitors in the treatment of various types of cancer.
引用
收藏
页码:96 / 107
页数:12
相关论文
共 50 条
  • [41] Tyrosine Kinase Update: Role and Response in Cancer Therapy
    Irby, Rosalyn B.
    Jiang, Yixing
    CURRENT CANCER THERAPY REVIEWS, 2011, 7 (02) : 155 - 166
  • [42] Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective
    Russo, Eleonora
    Spallarossa, Andrea
    Tasso, Bruno
    Villa, Carla
    Brullo, Chiara
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)
  • [43] Tyrosine kinase inhibitors for the therapy of anaplastic thyroid cancer
    Antonelli, Alessandro
    Fallahi, Poupak
    Ulisse, Salvatore
    Ferrari, Silvia Martina
    Mazzi, Valeria
    Di Domenicantonio, Andrea
    Miccoli, Paolo
    INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY, 2015, 2 (02) : 135 - 142
  • [44] Antiangiogenic therapy of cancer by multitargeted tyrosine kinase inhibitors
    Agata, Naoki
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2008, 106 : 40P - 40P
  • [45] A concise synthesis of a novel antiangiogenic tyrosine kinase inhibitor
    Payack, JF
    Vazquez, E
    Matty, L
    Kress, MH
    McNamara, J
    JOURNAL OF ORGANIC CHEMISTRY, 2005, 70 (01): : 175 - 178
  • [46] Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies
    Medves, Sandrine
    Demoulin, Jean-Baptiste
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2012, 16 (02) : 237 - 248
  • [47] Multi-targeted tyrosine kinase inhibitors for the treatment of nonsmall cell lung cancer: an era of individualized therapy
    Zhou, Caicun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2012, 1 (01) : 72 - 77
  • [48] Major Molecular Response in CML Patients Treated with Tyrosine Kinase Inhibitors: The Paradigm for Monitoring Targeted Cancer Therapy
    Press, Richard D.
    ONCOLOGIST, 2010, 15 (07): : 744 - 749
  • [49] Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies
    Ou, Xuejin
    Gao, Ge
    Habaz, Inbar A.
    Wang, Yongsheng
    MEDCOMM, 2024, 5 (09):
  • [50] Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
    Bolcaen, Julie
    Nair, Shankari
    Driver, Cathryn H. S.
    Boshomane, Tebatso M. G.
    Ebenhan, Thomas
    Vandevoorde, Charlot
    PHARMACEUTICALS, 2021, 14 (07)